GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Catalyst Pharmaceutical Partners, Inc. (CPRX) [hlAlert]

Rating:
Buy CPRX
up 24.48 %

Catalyst Pharmaceutical Partners, Inc. (CPRX) rated Buy with price target $4 by Maxim Group

Posted on: Tuesday,  Sep 24, 2013  8:25 AM ET by Maxim Group

Maxim Group rated Buy Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) on 09/24/2013, when the stock price was $2.94.
Since then, Catalyst Pharmaceutical Partners, Inc. has gained 24.49% as of 01/22/2016's recent price of $3.66.
If you would have followed this Maxim Group's recommendation on CPRX, you would have gained 24.48% of your investment in 850 days.

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive-compulsive disorders. Its product candidate CPP-109, which is the version of the chemical compound gamma-vinyl-GABA, referred to as vigabatrin. As of December 31, 2008, the Company was conducting two clinical trials of CPP-109, one evaluating its use in the treatment of cocaine addiction, and a second evaluating its use in the treatment of methamphetamine addiction. CPP-109 has the potential to treat other addictions, including addictions to nicotine, prescription pain, medications, alcohol, and marijuana, as well as obsessive-compulsive disorders, such as obesity and compulsive gambling.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/24/2013 8:25 AM Buy
None
2.94 4.00
as of 12/13/2013
1 Week down  -0.51 %
1 Month up  45.45 %
3 Months down  -34.69 %
1 YTD down  -34.69 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy